Restoring Alveolar Integrity in IPF: Targeting AT2 Receptor Biology with ATRAGs & Advancing Disease Modifying Potential in the Phase 2b ASPIRE Trial
- Exploring how dysfunction of alveolar type 2 (AEC2) cells drives loss of lung integrity and initiates fibrotic remodeling, positioning epithelial repair as a novel therapeutic strategy
- Understanding how angiotensin II type 2 receptor agonists (ATRAGs), including buloxibutid, activate protective signaling pathways to promote alveolar repair, restore tissue homeostasis, and reduce fibrotic progression
- Reviewing the design of the global, randomized, placebo controlled ASPIRE study evaluating buloxibutid over 52 weeks, including its focus on FVC outcomes, background standard-of-care integration, and potential to demonstrate disease-modifying effects in IPF